Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis

Two randomized, open-label, noninferiority phase 3 trials compared the prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with incident or prevalent chronic kidney disease who were undergoing dialysis. Vadadustat was noninferior to darbepoetin alfa with respect to cardiovascul...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 384; no. 17; pp. 1601 - 1612
Main Authors: Eckardt, Kai-Uwe, Agarwal, Rajiv, Aswad, Ahmad, Awad, Ahmed, Block, Geoffrey A, Bacci, Marcelo R, Farag, Youssef M.K, Fishbane, Steven, Hubert, Harold, Jardine, Alan, Khawaja, Zeeshan, Koury, Mark J, Maroni, Bradley J, Matsushita, Kunihiro, McCullough, Peter A, Lewis, Eldrin F, Luo, Wenli, Parfrey, Patrick S, Pergola, Pablo, Sarnak, Mark J, Spinowitz, Bruce, Tumlin, James, Vargo, Dennis L, Walters, Kimberly A, Winkelmayer, Wolfgang C, Wittes, Janet, Zwiech, Rafal, Chertow, Glenn M
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 29-04-2021
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two randomized, open-label, noninferiority phase 3 trials compared the prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with incident or prevalent chronic kidney disease who were undergoing dialysis. Vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-3
ObjectType-Feature-4
content type line 23
ObjectType-Undefined-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2025956